Deplete SPP1 macrophages to block disease.
- A therapeutic approach pioneered by the first monoclonal antibody therapy developed for cancer, anti-CD20, is to eliminate the offending cells.
- Examining single cell RNA-sequencing data from fibrotic lungs we identified our highly specific target:
- selectively expressed by SPP1 macrophages
- We are developing a therapeutic based on a high affinity camelid antibody (nanobody) engineered to deplete SPP1 macrophages.